Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer

Abstract

Elinzanetant led to a significantly lower frequency of vasomotor symptoms associated with endocrine therapy than placebo. (Funded by Bayer; OASIS-4 ClinicalTrials.gov number, NCT05587296.).